Sophia Genetics SA (STU:90B)

Q2 2025 Sophia Genetics SA Earnings Call Transcript

Aug 5, 2025 / 12:00 PM GMT

Release Date Price: €2.84 (+1.43%)

Transcript

Key Points

Positve

Sophia Genetics SA (SOPH) reported a 16% year-over-year revenue growth, with a 20% increase when excluding biopharma, indicating strong performance in its core business.
The company signed a record 35 new customers in Q2, bringing the total to 63 new customers for the year, showcasing strong business momentum.
Sophia Genetics SA (SOPH) announced a significant multi-year partnership with AstraZeneca, focusing on AI-powered predictive models for breast cancer treatment, highlighting its capabilities in AI and data analytics.
The company achieved a 35% year-over-year reduction in cash burn, demonstrating improved financial efficiency.
Sophia Genetics SA (SOPH) reported a 74.4% adjusted gross margin, an improvement of 120 basis points year-over-year, reflecting effective cost management and platform optimization.

Negative

Biopharma sector continues to present headwinds, impacting overall revenue growth despite strong performance in other areas.
Operating expenses increased by 19% year-over-year, driven by higher sales and marketing expenses and foreign exchange impacts.
The company reported an adjusted operating loss of $12.6 million, a 27% increase from the previous year, indicating ongoing financial challenges.
Sophia Genetics SA (SOPH) experienced a 5% revenue churn, with some small accounts being churned out, which could affect future revenue stability.
The company faces foreign exchange headwinds, which have impacted reported expenses and could continue to affect financial results due to macroeconomic uncertainties.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SOPH.OQ - Sophia Genetics SA
Q2 2025 Sophia Genetics SA Earnings Call
Aug 05, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning. My name is Danny, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Sophia Genetics 2nd quarter 2025 earnings conference call. Please note that all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press 0 for the operator.

This call is being recorded on Tuesday, August 5th, 2025. I would now like to turn the conference over to Kellen Sanger, Sophia Genetics, head of strategy and Investor relations. You may begin. Thank.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.